Last reviewed · How we verify
Enavogliflozin 0.3mg
At a glance
| Generic name | Enavogliflozin 0.3mg |
|---|---|
| Sponsor | Seoul St. Mary's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy (PHASE4)
- To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus
- Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus
- Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
- ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy (PHASE4)
- Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults (PHASE1)
- Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients (PHASE3)
- Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enavogliflozin 0.3mg CI brief — competitive landscape report
- Enavogliflozin 0.3mg updates RSS · CI watch RSS
- Seoul St. Mary's Hospital portfolio CI